TMPRSS2 protein facilitates SARS-CoV-2 entry via unexpected pathway

How exactly do Sars-Cov-2 particles enter host cells? An international team led by Dr Richard Brown from Dr Daniel Todt's Computational Virology group at the Department of Molecular and Medical Virology at Ruhr University Bochum, Germany, together with researchers from the Paul-Ehrlich-Institut, investigated this question. The researchers were able to show how the protein TMPRSS2 acts as a helper to bring the virus into the cell via the receptor ACE2. This TMPRSS2-mediated uptake significantly alters the immune response of the host cells and drives the evolution of the virus. They also showed that this applies to early variants of the virus as well as the more recent Omicron variant, and functions not only in humans, but likely also in wild, domestic and farm animals. The researchers report their findings in the journal PNAS from May, 30, 2024.

A role for endosomes?

It is undisputed that the presence of TMPRSS2 makes the entry of virus particles into host cells more efficient, but there were still many unanswered questions: How exactly does cell entry improve? What happens in the cell afterwards? Does this effect only work in humans?"

Dr. Richard Brown from Dr Daniel Todt's Computational Virology group at the Department of Molecular and Medical Virology at Ruhr University Bochum

To get to the bottom of these questions, the researchers used an electron microscope to directly compare viral entry into cells expressing either the ACE2 receptor alone, with cells that express both ACE2 and TMPRSS2 together. As expected, they were able to see that the presence of TMPRSS2 improved virus uptake.

"Contrary to previous assumptions, however, it was shown that TMPRSS2-mediated cell entry is associated with increased virus uptake into specific cellular vesicles: endosomes," explains Brown. "Until now, this entry pathway was thought to bypass endosomes. These observations were unexpected and further detailed studies are needed."

Furthermore, the researchers observed that the more recent Omicron variant also benefits from the presence of the TMPRSS2 protein in the same way as older variants. "Although the Omicron variant does not require TMPRSS2 to enter, virus uptake into host cells is also significantly increased when it is present," says Brown.

What happens after entry

The researchers also wanted to know what happens after the virus particles enter the host cells. They were able to show that for all tested variants, a more efficient TMPRSS2-mediated entry into host cells led to increased viral genome replication, followed by increased virus production. Infected cells react to this with a stronger immune response, which leads to faster death. The increased immune response has an influence on the evolution of the virus. If the host cells react more strongly, viruses with certain mutations prove to be advantageous and prevail.

The entry enhancing effects of TMPRSS2 are not limited to human hosts, but can also be observed in other mammals, including so-called reservoir species, which are natural hosts of coronaviruses in the wild. "Taken together, our data confirm that TMPRSS2 broadly promotes initial infection at the virus-host interface and influences the outcome of infection, with different mammalian species having the potential to influence the ongoing evolution of Sars-Cov-2," summarizes Richard Brown.

Funding

The work was funded by the Federal Ministry of Health grant Charis 6a, the German Centre for Infection Research, the Federal Ministry of Education and Research (funding codes 01KI2106 and 01KI2113), the Excellence Cluster Loewe DRUID, the State of Hesse and the Rudolph Marx Foundation.

Source:
Journal reference:

Qu, B., et al. (2024). TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution. PNAS. doi.org/10.1073/pnas.2407437121.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer